Don't know if MEDX has any lurking converts, but it now joins the thread. Couldn't see what might do this to MEDX, except that it is considered a poor man's ABGX (at least by me, FWIW), and since ABGX is down, MEDX must also be sold to keep parity. In the case of ABGX, I think the market has offered to do something stupid. It appears to be down in sympathy with AZN. ABX-EGF has the same target, but is in a different class, and AZN's hit today comes from bad trial design for Iressa, not a bad target.
Today I sold some dogs to raise cash for class efforts that seem significantly undervalued. ABGX is on the latter list, and I will be looking to add tomorrow. Though I'll be watching the open, rather than putting in an order tonight. The market may also be offering to do something stupid with MEDX, but I don't know it, and always mistrusted the nepotistic MEDX/Genmab axis.
Cheers, Tuck |
